These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8823511)
41. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Perlík F; Masri MA; Rost M; Kamarád V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):309-13. PubMed ID: 16601778 [TBL] [Abstract][Full Text] [Related]
43. [Therapeutic monitoring of cyclosporine A]. Komzáková I; Safarcík K; Brozmanová H; Grundmann M Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901 [TBL] [Abstract][Full Text] [Related]
45. Biotransformation of valdecoxib by microbial cultures. Keshetti S; Ciddi V J Microbiol Biotechnol; 2010 Apr; 20(4):809-16. PubMed ID: 20467258 [TBL] [Abstract][Full Text] [Related]
46. Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestatic action? Fricker G; Fahr A Yale J Biol Med; 1997; 70(4):379-90. PubMed ID: 9626758 [TBL] [Abstract][Full Text] [Related]
47. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats. Yang ZQ; Xu J; Pan P; Zhang XN Pharmazie; 2009 Jan; 64(1):26-31. PubMed ID: 19216227 [TBL] [Abstract][Full Text] [Related]
48. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452 [TBL] [Abstract][Full Text] [Related]
49. The effective therapy of cyclosporine A with drug delivery system in experimental colitis. Fukata N; Uchida K; Kusuda T; Koyabu M; Miyoshi H; Fukui T; Matsushita M; Nishio A; Tabata Y; Okazaki K J Drug Target; 2011 Jul; 19(6):458-67. PubMed ID: 20804404 [TBL] [Abstract][Full Text] [Related]
50. Bioequivalence of Neoplanta capsule to Sandimmune Neoral, microemulsion formulations of cyclosporin A in human subjects. Lee YJ; Chung SJ; Shim CK Int J Clin Pharmacol Ther; 1998 Apr; 36(4):210-5. PubMed ID: 9587047 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Kato M; Sakai H; Takahashi M; Miura I Am J Ther; 2014; 21(5):377-84. PubMed ID: 23011175 [TBL] [Abstract][Full Text] [Related]
52. Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. Dai W; Guo Y; Zhang H; Wang X; Zhang Q Int J Pharm; 2015 Jan; 478(2):718-25. PubMed ID: 25448562 [TBL] [Abstract][Full Text] [Related]
53. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758 [TBL] [Abstract][Full Text] [Related]
54. Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy. Ishizawa T; Sugawara Y; Ikeda M; Hasegawa K; Makuuchi M Transplant Proc; 2005 Dec; 37(10):4370-2. PubMed ID: 16387123 [TBL] [Abstract][Full Text] [Related]
56. Microbial conversion of nigericin in three successive steps, by Sebekia benihana. Delort AM; Jeminet G; Sancelme M; Dauphin G J Antibiot (Tokyo); 1988 Jul; 41(7):916-24. PubMed ID: 3417565 [TBL] [Abstract][Full Text] [Related]
57. Uptake and metabolism of cyclosporin A and SDZ IMM 125 in the human in vitro skin2 dermal and barrier function models. Vickers AE; Biggi WA; Dannecker R; Fischer V Life Sci; 1995; 57(3):215-24. PubMed ID: 7596228 [TBL] [Abstract][Full Text] [Related]
58. Microbial models of mammalian metabolism. Fungal metabolism of phenolic and nonphenolic p-cymene-related drugs and prodrugs. II. Metabolites of nonphenolic derivatives. Moussa C; Houziaux P; Danree B; Azerad R Drug Metab Dispos; 1997 Mar; 25(3):311-6. PubMed ID: 9172948 [TBL] [Abstract][Full Text] [Related]
59. Hepatocellular effects of cyclosporine A and its derivative SDZ IMM 125 in vitro. Wolf A; Schramm U; Fahr A; Aicher L; Cordier A; Trommer WE; Fricker G J Pharmacol Exp Ther; 1998 Mar; 284(3):817-25. PubMed ID: 9495838 [TBL] [Abstract][Full Text] [Related]
60. [Effects of cyclosporine A on the reactivity of the aorta with regenerated endothelium in rats]. Dagenais F; Hollmann C; Buluran J; Cartier R Ann Chir; 1995; 49(8):694-9. PubMed ID: 8561423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]